# Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell)

> **NCT06734832** · PHASE3 · RECRUITING · sponsor: **Sinovac Biotech Co., Ltd** · enrollment: 8000 (estimated)

## Conditions studied

- Hand, Foot, and Mouth Disease（HFMD)

## Interventions

- **BIOLOGICAL:** bivalent enterovirus vaccine (Vero cell), inactivated
- **BIOLOGICAL:** Enterovirus Type 71 Vaccine (Vero Cell), Inactivated

## Key facts

- **NCT ID:** NCT06734832
- **Lead sponsor:** Sinovac Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-13
- **Primary completion:** 2025-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 8000 (ESTIMATED)
- **Last updated:** 2025-01-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06734832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06734832, "Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06734832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*